ocgn-20200716xex991 Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: July 2020 Forward Looking Statement This presentation contains forward-looking statements that involve
Thursday, July 16, 2020 BiopharmaWatch Research 1 min read
Key Takeaway: Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: July 2020
Ocugen's Modifier Gene Therapy Platform Breakthrough Technology designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 6
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+79%
120-day peak, hindsight
Typical move
3.6%
average across 4 past catalysts
Cash runway
~24 mo
Low dilution risk
Lead asset
OCU200
Phase 1 · Center Involved Diabetic Macular Edema
Full Press Release Details
Our Mission is to Develop Gene Therapies to Cure Blindness Diseases NASDAQ: OCGN Corporate Deck: July 2020
Ocugen's Modifier Gene Therapy Platform Breakthrough Technology designed to Address Multiple Diseases with One Product Approach Complex Diseases Through Multiple Factors 6